REG - Inspiration Health - Trading update and notice of results

Inspiration HealthcareAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250820:nRST9616Va&default-theme=true

RNS Number : 9616V  Inspiration Healthcare Group PLC  20 August 2025

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Trading update for six months ended 31 July 2025

Notice of interim results

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company pioneering best-in-class, specialist neonatal intensive care medical
devices, provides a trading update for six months ended 31 July 2025.

 

Highlights

·    Revenue growth of 41% to £24.0 million (H1 FY25: £17.0 million)

·    Improved gross margins due to favourable product mix including strong
sales of capital items

·    $6 million humanitarian aid contract fully delivered in the period

·    Strong sales momentum in H1 FY26 expected to continue into H2 FY26

·    Net debt reduced by £1.6 million to £6.7 million (31 January 2025:
£8.3 million), strengthening the balance sheet

 

Revenues for the period were £24.0 million (H1 FY25: £17.0 million) which is
a 41% increase on the same period last year, ahead of market expectations, and
represents record half year revenues for the Group reflecting the benefits of
the back-to-basics approach implemented last year. Gross margins also
recovered benefitting from an improved sales mix of higher margin neonatal
products, with strong sales of capital items, leading to improved
profitability when combined with the impact of cost savings implemented last
year.

 

The Group's contract with the global humanitarian aid group focusing on child
and infant welfare, the largest single contract the Company has won to date,
at $6 million for SLE6000 and SLE1500 ventilators plus associated accessories
and consumables was fully delivered in the period and a majority of payment
received. The remainder of this payment, relating to installation of the
equipment, is expected to be received in early H2.

 

The Middle Eastern contract is also progressing, with the first shipment of
ventilators and accessories delivered in the period and payment received. The
remainder of this is contract is expected to be delivered in H2 pending
receipt of a letter of credit.

 

At 31 July 2025, the Group's net debt (excluding IFRS16 lease liabilities) was
£6.7 million, a reduction of £1.6 million from £8.3 million at 31 January
2025 due to the strong trading performance in the period combined with an
improving working capital position, with a further improvement in net debt
expected to be realised in the second half.

 

Raffi Stepanian, CEO of Inspiration Healthcare plc commented: "I am pleased to
report that we have had a robust first half performance and continue to see
the benefits of our turnaround strategy. With strong revenue growth of 41%,
enhanced gross margins, a significant improvement in EBITDA and a reduction in
net debt, we are seeing clear evidence that our disciplined 'back-to-basics'
approach is driving financial recovery and setting a solid foundation for
continued momentum into the second half of the year and beyond.

 

"Our pipeline is strong and we are continuing an upward trajectory. We remain
confident in delivering our full-year expectations and creating long-term
value for shareholders."

 

Notice of interim results

The Group will be announcing its interim results for the six months ended 31
July 2025 on Tuesday, 7 October 2025. Analyst and investor meetings will take
place to accompany the results, details of which will be announced in due
course.

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                          Tel: +44 (0)330
                                           175 0000
 Raffi Stepanian, Chief Executive Officer

 Alan Olby, Chief Financial Officer

 Panmure Liberum (Nominated Adviser & Broker)                                                                        Tel: +44 (0)20
                                                                                     3100 2000
 Will Goode

 Emma Earl

 Will King

 Walbrook PR Ltd (Media & IR)              Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
 Anna Dunphy                               Mob: +44 (0) 7876 741 001
 Rachel Broad                              Mob: +44 (0) 7747 515 393

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets
pioneering medical technology. Based in the UK, the Company specialises in
neonatal intensive care medical devices, which are addressing a critical need
to help to save the lives and improve the outcomes of patients, starting with
the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy.  In the rest of the world the Company has
an established network of distribution partners around the world giving access
to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and in the USA from its facility in
Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found
at www.inspirationhealthcaregroup.com
(http://www.inspirationhealthcaregroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFVETDIALIE